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Decreased thickness of the retinal nerve fiber layer (RNFL)may reflect retinal neuronal-ganglion cell death. A decrease in the RNFL
has been demonstrated in Alzheimer’s disease (AD) in addition to aging by optical coherence tomography (OCT). Twenty-three
mild-AD patients and 28 age-matched control subjects with meanMini-Mental State Examination 23.3 and 28.2, respectively, with
no ocular disease or systemic disorders affecting vision, were considered for study. OCT peripapillary and macular segmentation
thickness were examined in the right eye of each patient. Compared to controls, eyes of patients with mild-AD patients showed no
statistical difference in peripapillary RNFL thickness (𝑃 > 0.05); however, sectors 2, 3, 4, 8, 9, and 11 of the papilla showed thinning,
while in sectors 1, 5, 6, 7, and 10 there was thickening. Total macular volume and RNFL thickness of the fovea in all four inner
quadrants and in the outer temporal quadrants proved to be significantly decreased (𝑃 < 0.01). Despite the fact that peripapillary
RNFL thickness did not statistically differ in comparison to control eyes, the increase in peripapillary thickness in our mild-AD
patients could correspond to an early neurodegeneration stage and may entail the existence of an inflammatory process that could
lead to progressive peripapillary fiber damage.
1. Introduction
Alzheimer’s disease (AD), themost common cause of demen-
tia, afflicts 67 of every 1000 persons over age 65. Its prevalence
and incidence increase exponentially with age [1, 2]. In 2006,
the worldwide prevalence of Alzheimer’s was 26.6 million,
and by 2050, the prevalence will quadruple, meaning that by
that time 1 in 85 persons worldwide will be living with the
disease [2].
AD is characterized by a decline in cognitive function,
loss of learning and memory, and the formation of neuritic
plaques and neurofibrillary tangles, primarily in the cerebral
cortex [3, 4].
The retina is a projection of the brain, and a number
of similarities between AD pathology and several distinct
retinal degenerations have been described [5, 6]. The retinal
nerve fiber layer (RNFL) is composed of retinal-ganglion cell
axons that form the optic nerve. Decreased thickness of the
RNFL can reflect retinal neuronal-ganglion cell death and
axonal loss in the optic nerve [7, 8].
The RNFL reportedly thins with aging [9, 10]. Some stud-
ies have also shown a decrease of the RNFL in AD in addition
to aging [7, 8, 11–16]. Hinton et al. [17] were the first to show
histopathological evidence of retinal-ganglion cell loss and
optic-nerve degeneration in patients with AD.These findings
were then confirmed in several follow-up studies [18–21].
Indeed, the largemagnocellular cell axon degeneration in AD
has been documented [19, 22]. Other histopathology studies
[23–28], however, have failed to confirm these findings and
suggest that methodological differences were responsible for
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the contradictory results, due to a different postmortem delay
in axon count or difficulties in obtaining well-preserved
myelinated axons.
Currently it is thought that retinal ganglion cell (RGC)
loss in AD might result from amyloid deposits in the eye
and/or retina. Amyloid-beta plaques aswell as oligomers have
been reported in postmortem retinal tissue from patients
with AD and in a mouse model of AD, as well as in human
retinal tissue in vivo [29]. Therefore, amyloid accumulation
in the eye or retina of patients with AD may result in
the degeneration of RGC in parallel to amyloid-beta-related
neurodegeneration in the brain [29].
Diagnosis and progression of AD, especially early cases,
are complicated because of imprecise neuropsychological
testing, sophisticated but expensive neuroimaging tech-
niques, and invasive sampling of cerebrospinal fluid [30, 31].
Improved methods for screening and early detection are
essential to identify cognitively normal individuals who have
a high risk of developing AD, so that treatment can be devel-
oped to delay the progression of the disease [32]. Currently,
there is no definitive antemortem diagnosis for AD, and new
biomarkers for diagnosis are therefore needed. Over the last
few decades, very accurate tools for analyzing the eye fundus
have been developed (i.e., OCT, laser polarimetry), opening
new ways of examining the retina in vivo.
OCT is a reliable noninvasive technique, routinely used
in ophthalmology to visualize and quantify the layers of the
retina. OCT enables quantitative cross-sectional imaging of
the RNFL and macular volume. A recent study published
by our group [33] has shown that in mild-AD patients
the first affected area of the retina is the macular area. As
the neurodegeneration progresses, a significant decline in
peripapillary RNFL thickness will become apparent.
The goal of the present study was to examine in detail
peripapillary and macular segmentation in order to deter-
mine which is the earliest thinned area in patients with mild
AD which may be used, in the future, as a predictive tool.
2. Material and Methods
2.1. Subjects. To select patients, we reviewed the Database
of the Memory Unit of the Hospital Clinico San Carlos in
Madrid (Spain), consisting of a total of 2635 patients. First,
we excluded the patients with a Global Deterioration Scale
(GDS) over 4 and then those with a mood or psychiatric
disorder. Next, we took into account 87 patients with mild
AD. These patients, according to the National Institute of
Neurological and Communicative Disorders and Stroke-AD
and Related Disorders Association and the Diagnostic and
Statistical Manual ofMental Disorders IV, hadmild cognitive
impairment according to the Clinical Dementia Rating
scale. Then ophthalmic medical records of these patients
were reviewed, excluding patients who were previously
diagnosed with an ophthalmological pathology (glaucoma
or suspected glaucoma, media opacity, and retinal diseases).
After this analysis, 29 patients with AD satisfied all the
requirements to participate in the study (GDS over 4 and
free of ocular disease and systemic disorders affecting vision
in their medical record). Of the 29 mild-AD patients and 37
age-matched control subjects selected (normal MMSE
scores), 6 mild-AD patients and 9 age-matched control
subjects were subsequently excluded due to posterior
pole pathology including macular degeneration, drusen,
suspicion of glaucoma, glaucoma, epiretinal membrane, or
cataract that prevented ocular examination. Because of this
selection, 23 patients with mild AD and 28 age-matched
control subjects were considered for the study. Informed
consent was obtained from both groups. The research
followed the tenets of the Declaration of Helsinki, and the
protocol was approved by the local ethics committee.
2.2. Methods. For the ophthalmological part of the study, the
right eye of each patient was analyzed. All participants met
the following inclusion criteria: being free of ocular disease,
AREDS Clinical Lens Standards <2, retinal drusen, and
systemic disorders affecting vision; having a best corrected
VA of 20/40; having a ±5 spherocylindrical refractive error;
and having intraocular pressure of less than 20mmHg. For
screening, all AD patients and control subjects underwent a
complete ophthalmologic examination, including assessment
of VA, refraction, anterior segment biomicroscopy, appla-
nation tonometry (Perkins MKII tonometer, Haag Streit-
Reliance Medical, Switzerland), dilated fundus examination,
and OCT. The RNFL thickness and macular thickness were
measured by OCT Model 3D OCT-1000 (Topcon, Japan)
after pupil dilatation. The RNFL thickness was scanned 3
consecutive times per patient in each area studied. The mean
values were considered for statistical analysis. All tests were
performed by the same optometrist (ESG) under the same
conditions. These tests were selected considering that in
this developmental stage of the disease the results were not
influenced by the patient’s cognitive impairment.
The peripapillary RNFL thickness parameters evaluated
in this study were average thickness (360∘ measurement),
thickness for each 12-o’clock hour position with the 3-o’clock
position as nasal, 6-o’clock position as inferior, 9-o’clock posi-
tion as temporal, and 12-o’clock position as superior. Macular
RNFL thickness data were displayed in three concentric rings
centered in the foveola that were distributed as follows: a
central macular ring, 1mm away from the fovea; an inner
macular ring, 3mm away from the fovea; and an outer
macular ring, 6mm away from the fovea. As a result, the total
area studied made up a 6mm macular map. In addition, the
inner and outer rings were each divided into four quadrants
(superior, inferior, nasal, and temporal) (Figure 1). The total
volume of the macula as provided by the OCT was also
calculated. The good scan criteria were determined as the
signal-to-noise ratio >30 and accepted A-scans >95% in fast
RNFL scanning. All measurements are given in microns,
according to the calibration provided by the manufacturers
and the total volume in mm3.
2.3. Statistical Analysis. The data are reported as mean values
± SD. The differences between mild AD and control eyes
were analyzed using the Mann-Whitney test. Data for the
statistical analysis were introduced and processed in a SPSS
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Figure 1: OCT report of retinal nerve fiber layer (RNFL) thickness analysis. (a) Peripapillary OCT. The thickness for each 12-o’clock hour
position with the 3-o’clock position as nasal, 6-o’clock position as inferior, 9-o’clock position as temporal, and 12-o’clock position as superior
was evaluated. (b)Macular OCT.Diagram showing the concentric rings and quadrants considered for analysis of themacular RNFL thickness
and measurements automatically provided by the analyzer.
19.0 (SPSS Inc©, Inc, Chicago, IL, USA). A 𝑃 value of <0.05
was considered statistically significant.
3. Results
Demographic and clinical data for the mild-AD patients and
control group are shown in Table 1. No statistically significant
differences in age, gender, or educational level were found
between the study groups. The MMSE scores in mild-AD
patients were significantly decreased in comparisonwith age-
matched control subjects (Table 1). All mild-AD patients had
MMSE values higher than 17.
3.1. Optical Coherence Tomography
Peripapillary RNFL Segmentation Thickness. Peripapillary
RNFL thickness values (Figure 2(a)) showed no statistical
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Figure 2: Mean data of RNFL thickness against eye quadrants assessed with optical coherence tomography (OCT). (a) Peripapillary
segmentation retinal nerve fiber layer, (b) Central macular ring (1mm away from the fovea). (c) Inner macular ring (3mm away from the
fovea). (d) Outer macular ring (6mm away from the fovea). ∗𝑃 value < 0.01.
Table 1: Demographic and clinical data of the study groups.
AD Control
𝑃 value(𝑛 = 23) (𝑛 = 28)
Age§ 79.3 ± 4.6 72.3 ± 5.1 0.274
Gender
Male 9 9 0.615Female 14 19
Race Caucasian Caucasian
MMSE§ 23.3 ± 3.1 28.2 ± 1.9 0.001∗Range (17–29) Range (25–31)
§Mean value± SD; ∗𝑃 < 0.01 [AD,Alzheimer’s disease;MMSE,Mini-Mental
State Examination; SD, standard deviation].
difference between mild-AD patients and control subjects
(Table 2).
Although the differences were not significant in any of the
sectors, it was shown that peripapillary sectors 2, 3, 4, 8, 9, 11,
and 12 were thinner in the mild-AD patients than in controls;
in peripapillary sectors 1, 5, 6, 7, and 10 the retina in mild-AD
patients was thicker with respect to the control (Figure 2(a);
Table 2).
Macular RNFL Thickness and Total Volume. As we reported
in a previous study [33] the analysis of the RNFL revealed
that, in patients with mild AD, the values for the central
ring (fovea) (Figure 2(b)) and the four inner quadrants (3mm
from the fovea) (Figure 2(c)) were significantly decreased in
comparison with control subject (𝑃 < 0.05 in both instances;
Mann-Whitney 𝑈 test) (Table 2). The RNFL thickness of the
outermacular quadrants (6mm from the fovea) (Figure 2(d))
in patients with mild AD was diminished in comparison
with control subjects; however, only the values of the outer
temporal quadrant were significantly lower (𝑃 < 0.05; Mann-
Whitney 𝑈 test) (Table 2).
The total macular volume was significantly reduced in
mild-AD patients in comparison with control subjects (𝑃 <
0.05; Mann-Whitney 𝑈 test) (Table 2).
4. Discussion
Alzheimer’s dementia syndromes, like all neurodegenerative
diseases, lack objective disease- and stage-specific biomarkers
[34]. As a part of the CNS, the retina or neural portion
BioMed Research International 5
Table 2: RNFL thickness and total macular volume.
Retinal area of study AD group§ Control group§ % RNFL decrease 𝑃 value
Peripapillary thickness (𝜇m)
Sector 1 101.2 ± 24.4 100.0 ± 16.9 1.24 0.790
Sector 2 96.8 ± 20.8 100.4 ± 14.4 −3.62 0.618
Sector 3 80.1 ± 22.9 90.8 ± 16.0 −11.85 0.084
Sector 4 60.5 ± 18.3 65.4 ± 10.3 −7.60 0.464
Sector 5 73.7 ± 12.7 68.3 ± 11.3 7.83 0.173
Sector 6 101.4 ± 23.7 99.3 ± 19.0 2.02 0.790
Sector 7 119.4 ± 19.1 116.3 ± 21.9 2.62 0.756
Sector 8 111.7 ± 21.6 114.5 ± 24.5 −2.48 0.564
Sector 9 66.3 ± 18.2 67.5 ± 16.5 −1.80 0.877
Sector 10 60.7 ± 13.8 57.3 ± 9.6 5.99 0.464
Sector 11 77.0 ± 20.6 78.5 ± 14.7 −1.96 0.94
Sector 12 101.3 ± 27.1 110.7 ± 15.8 −8.45 0.335
Foveal thickness (𝜇m) Fovea 221.2 ± 21.6 243.7 ± 24.8 −9.24 0.015∗
Inner macular quadrant (𝜇m)
Superior area 283.4 ± 11.1 294.9 ± 18.1 −3.91 0.002∗
Inferior area 279.8 ± 18.1 295.8 ± 13.5 −5.40 0.002∗
Nasal area 285.6 ± 17.2 300.1 ± 15.1 −4.83 0.007∗
Temporal area 273.1 ± 12.7 285.2 ± 14.6 −4.22 0.002∗
Outer macular quadrant (𝜇m)
Superior area 245.4 ± 12.5 252.1 ± 13.7 −2.65 0.084
Inferior area 242.8 ± 17.4 245.2 ± 13.9 −0.99 0.531
Nasal area 263.7 ± 12.1 267.5 ± 19.1 −1.41 0.110
Temporal area 228.0 ± 18.8 238.5 ± 12.3 −4.43 0.009∗
Total macular volume (mm3) 7.1 ± 0.3 7.3 ± 0.3 9.34 0.024∗
§Mean value ± SD; ∗𝑃 < 0.05 [AD, Alzheimer’s disease; RNFL: retinal nerve fiber layer; SD, standard deviation].
of the eye shares many features with the brain, including
embryological origin as well as anatomical and physiological
characteristics. Its peripheral location provides an accessible
andnoninvasiveway of examining brain pathology [35].OCT
is a reliable noninvasive technique that enables quantitative
cross-sectional imaging of the RNFL [36].
Thinning of the RNFL has been found in several neu-
rological diseases, such as Parkinson’s disease [16, 37–39],
dementia with Lewy Bodies [16], amnestic mild cognitive
impairment [8, 15], neuromyelitis optica [40], migraine [41],
and AD [8, 11–17, 20, 27, 36, 37, 42–45]. The loss of RNFL
thickness in AD is linked to a depletion of retinal-ganglion
cells and optic-nerve axons [13, 14, 32, 46, 47]. It has been
postulated that the defects in RNFL may be the earliest sign
of AD, even prior to damage to the hippocampal region that
impairs memory [36]. In addition, published data suggest an
association between the thinning of RNFL and severity of AD
[8, 11].
In the present work, we compare the peripapillary RNFL
segmentation thickness, macular thickness, and the total
macular volume in mild-AD patients and age-matched con-
trol subjects. One of the relevant issues of the study was
that the sample analyzed here was homogeneous in that (i)
all patients had recently been diagnosed as having mild AD
(GDS 4, Reisberg scale [48]) with mean MMSE score values
of 23.7 ± 3.3; (ii) all the individuals were Caucasians; and (iii)
there were no significant differences in age or educational
level among the groups. The results of our study showed a
difference between the peripapillary RNFL segmentation and
themacula thickness in ourmild-AD patients in that only the
macular thickness was significantly decreased in comparison
with the control group.
Widespread axonal degeneration in the optic nerve was
found in a postmortem study of patients with AD [17].
Morphometric analysis of the whole-mount retina has shown
thatAlzheimer’s patients had a predominant loss of the largest
class of retinal-ganglion cells (M-cells), which could be a
primary process or a consequence of retrograde neurodegen-
eration occurring in the cortical regions [19]. In vivo studies
using different methodologies have confirmed optic-nerve-
fiber damage in AD when compared with controls. Optic
disc pallor, pathologic disc cupping, and thinning of the
neuroretinal rim and the RNFL have been reported in studies
based on the subjective evaluation of fundus photographs
[11, 42] and the optic-nerve analyzer [42].
There is controversy on the reduction of the peripapillary
RNFL thickness measured by OCT in AD. A reduction in the
thickness of all peripapillary RNFL quadrants asmeasured by
OCThas been reported [12, 43], and it has been suggested that
this morphologic abnormality is related to retinal dysfunc-
tion as revealed by abnormal patterns in electroretinogram
responses [43]. However, some OCT studies on peripapillary
thickness in AD [8, 13, 15, 16, 36, 44, 45, 49] found that the
RNFL thinning was restricted to the superior quadrant [13,
44, 50–52] or to the superior and inferior quadrants [15, 37,
45] in comparison with control subjects. Some studies have
6 BioMed Research International
correlated cognitive decline with decreased RNFL thickness
[33, 50, 53]. It has been suggested that the inferior quadrant of
theRNFLmay be amore specific and sensitive area than other
RNFL quadrants in predicting the deterioration of cognitive
status to reflect retinal abnormality in the early stages of AD
[15, 50]. The reason for the variability of the results among
studies could be related to MMSE scores. Thus, Parisi et al.
[43] and Iseri et al. [12], whose patients had more advanced
AD (ranges of MMSE scores 11 to 19 and 8 to 28, resp.),
showed a reduction in RNFL thickness in all peripapillary
quadrants. Kesler et al. [15], whose patients had a mean
MMSE score of 23.6, showed a decrease in the superior and
inferior peripapillary quadrants. By contrast, both Berisha
et al. [13], whose Alzheimer’s patients had higher MMSE
scores (17 to 30), and Paquet et al. [8], whose patients had
a mean MMSE score of 22.6, found a thickness reduction
only in the superior peripapillary quadrant, postulating this
finding as being the earliest peripapillary retinal damage
in AD patients. In our patients, with MMSE values similar
to those reported by Berisha and Paquet, the reduction of
mean peripapillary RNFL thickness did not reach statisti-
cal significance in comparison to control, but peripapillary
RNFL thickness diminished or increased, depending on the
segment studied. It should be noted that the thinning sectors
of papilla corresponded to 2, 3, 4, 8, 9, and 11, while sectors 1,
5, 6, 7, and 10 showed a thickening. These values differ from
those found in the same sectors of the controls but in any case
reach statistical significance.
Most authors, although working in more advanced stages
of disease (MMSE > 23.7), agree that the peripapillary
RNFL thinning is significant in the superior and inferior
sectors [13, 37, 44]. However, sectors 1, 5, 6, 7, and 10 in
our patients showed thickening. This dissimilarity could be
explained because of difference in the stage of the disease,
which in our case corresponded to a much earlier stage. This
tendency towards greater thickness, although not statistically
significant, could be related to the findings of Ascaso et al. in
themacula of patients withmild cognitive impairment (MCI)
and AD. Patients with MCI had greater RNFL thickness
compared to AD and controls, suggesting that this difference
could be caused by inflammation after gliosis neuronal
death [54]. Similarly, the increase in peripapillary thickness
in our mild-AD patients in the sectors 1, 5, 6, 7, and 10,
corresponding to the superior and inferior sectors, may
indicate a phase of inflammation and gliosis of neural tissue
prior to the degenerative process.
Reactive astrogliosis in the brain is a well-known feature
of AD, but its role in AD is not well understood. Reactive
astrogliosis tends to be focal in AD. Reactive astrocytes are
intimately associatedwith amyloid plaques or diffuse amyloid
deposits. Astrocytes surround them with dense layers of
processes as if formingminiature scars around them, perhaps
to wall them off and act as neuroprotective barriers [55]. It
is plausible that, in the early stages of the disease, microglial
activation could help remove amyloid plaques, while in
later phases proinflammatory cytokines induced bymicroglia
could contribute to neurodegenerative process [56, 57].
In the same way, retinal neurodegenerative diseases
are also associated with chronic microglial activation and
neuroinflammation. In the degenerating retina, endogenous
signals activate microglial cells, leading to their local prolif-
eration, migration, enhanced phagocytosis, and secretion of
cytokines, chemokines, and neurotoxins. These immunolog-
ical responses and the loss of limiting control mechanisms
may contribute significantly to retinal tissue damage and
proapoptotic events in retinal neurodegeneration [57–59]. A
limitation to be considered in our study, as well as those
reported in the literature on RNFL thickness evaluation
by OCT, is the number of patients included. Studies on
early-stage Alzheimer’s patients are difficult to perform, one
reason being that these patients usually come for diagnosis at
advanced stages of the disease. Taking this into consideration
and the homogeneity of the patients included in the present
work, we consider that our data provide preliminary evidence
to warrant a more extensive study.
5. Conclusions
In the present study, the analysis of the OCT values of both
peripapillary and macular RNFL thickness in patients with
mild AD (MMSE = 23.7) showed that only in the macula
was there a significant thickness reduction compared to
aged-matched controls. Our data, taken together with those
reported in the literature, move us to propose the hypothesis
that the first affected area of the retina in mild AD is the
macular area, where, due to the arrangement of themultilayer
bodies of the ganglion cells, the decrease is easier to detect.
Subsequently, as the neurodegeneration progresses, a sig-
nificant decline in peripapillary RNFL thickness will become
apparent.The study of the peripapillary segmentation reveals,
in a more accurate way, the changes that occur in RNFL
thickness in relation to the macular-thickness changes. In
this sense, our patients with mild AD differed with respect
to controls, althoughwithout reaching statistical significance;
perhaps due to the early stage of the disease. In addition, the
increase in peripapillary thickness in our mild-AD patients
may indicate the existence of an inflammatory process that
would lead to neurodegeneration of the peripapillary fibers.
More extensive studies should be conducted to test these
findings.
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